San Diego-dependent Viking Therapeutics marked by itself as a serious competitor inside the weight loss drug marketplace in February after revealing promising facts from the mid-phase trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as a weekly injection As well as in March the com